Lexaria Bioscience

LEXX · NASDAQ

$3.08+$0.09 (+3.01%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $2.99

LEXX analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $53.55 (+1638.6% upside)

Low: $22.73
Now: $3.08
High: $86.63

Upgrades and downgrades

The latest rating actions, newest first

LEXX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Dec 26, 2025	Maintains	Buy	$4.00 → $1.50	40%

The case for and against

Updated Jan 19, 2026

Bull case

Lexaria Bioscience Corp's outlook is bolstered by the anticipated enhancements in the safety profile of GLP-1 drugs, which may lead to reduced patient dropout rates and increased market acceptance. The company's cash position has improved, contributing to its ability to invest in its innovative DehydraTECH drug delivery technology, which enhances the bioavailability of a range of active pharmaceutical ingredients across various therapeutic areas. Additionally, the company projects an increase in shares outstanding to 33 million by the end of FY2026, indicating potential growth in market presence as it licenses its proprietary technology.

Bear case

Lexaria Bioscience Corp reported a significant net loss of $11.9 million for the fiscal year ending August 31, 2025, equating to a loss of $0.66 per share, indicating ongoing financial challenges. Additionally, the company experienced a net loss of $3.8 million for the third quarter of fiscal 2025, reinforcing concerns regarding its profitability and financial viability. The reductions in gastrointestinal adverse events associated with its DehydraTECH-semaglutide technology may not sufficiently offset the potential for drug discontinuation among users, further complicating the outlook for the company's licensing revenues.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.